Press 
Releases 

ARTICLES

Mursla Bio receives FDA Breakthrough Device Designation for EvoLiver™ test
Reflects the potential of EvoLiver™ test to improve early liver cancer detection among high-risk patients
Mursla Bio’s EvoLiver™ surpasses current standards in liver cancer surveillance, data presented at AASLD Liver Meeting 2024

EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with …

Mursla Bio joins leading European consortium to advance clinical applications based on extracellular vesicle science

Mursla Bio was selected to support scaling and commercialization strategy for extracellular vesicle-based disease surveillance and diagnostics …

Mursla Bio enters the US market with strategic expansion
Mursla Bio launches US strategy to bring its novel liquid biopsy tests – based on extracellular vesicle technology – to patients
NEXOS
Mursla Bio presents breakthrough liquid biopsy technology for extracellular vesicles in Cell Press
Novel and scalable analysis of extracellular vesicles sub-types detailed in Cell Press’ iScience